韩国妇科肿瘤学会宫颈癌管理实践指南的第五修订版纳入了基于 2020 年发布的 4.0 版本的最新研究成果和治疗策略的变化。每个关键问题都是通过关注最近的值得注意的见解和当代的关键问题而提出的。宫颈癌领域的问题。这些问题的重要性和对当前治疗的影响进行了评估，并由发展委员会通过投票最终确定。选定的关键问题如下：免疫检查点抑制剂作为复发或转移性宫颈癌一线或二线治疗的有效性和安全性；早期宫颈癌微创根治性子宫切除术的肿瘤学安全性；局部晚期宫颈癌同步放化疗后辅助全身治疗的有效性和安全性；以及前哨淋巴结定位与盆腔淋巴结清扫相比的肿瘤学安全性。该指南的建议、方向和优势基于系统评价和荟萃分析，并最终通过公开听证会和外部审查得到确认。在这项研究中，我们描述了修订后的宫颈癌治疗实践指南。© 2024。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

This fifth revised version of the Korean Society of Gynecologic Oncology practice guidelines for the management of cervical cancer incorporates recent research findings and changes in treatment strategies based on version 4.0 released in 2020. Each key question was developed by focusing on recent notable insights and crucial contemporary issues in the field of cervical cancer. These questions were evaluated for their significance and impact on the current treatment and were finalized through voting by the development committee. The selected key questions were as follows: the efficacy and safety of immune checkpoint inhibitors as first- or second-line treatment for recurrent or metastatic cervical cancer; the oncologic safety of minimally invasive radical hysterectomy in early stage cervical cancer; the efficacy and safety of adjuvant systemic treatment after concurrent chemoradiotherapy in locally advanced cervical cancer; and the oncologic safety of sentinel lymph node mapping compared to pelvic lymph node dissection. The recommendations, directions, and strengths of this guideline were based on systematic reviews and meta-analyses, and were finally confirmed through public hearings and external reviews. In this study, we describe the revised practice guidelines for the management of cervical cancer.© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.